A Study to Evaluate the Efficacy and Safety of VB-201 in Patients With Ulcerative Colitis
Status:
Completed
Trial end date:
2014-11-01
Target enrollment:
Participant gender:
Summary
This study will examine the safety and efficacy in subjects with mild to moderate ulcerative
colitis, as measured by Modified Mayo Score, Modified Baron Score, IBDQ, calprotectin and
other assessments.
Phase:
Phase 2
Details
Lead Sponsor:
Vascular Biogenics Ltd. operating as VBL Therapeutics